The Specialty Patent Cliff and the Payer Response
Johann Odermann, Senior Director, Advisory Services
Why the 2026-2034 LOE Wave Will Be Governed Less by Patent Dates Than by Payer Defection Timing
The biopharmaceutical industry is entering the largest loss-of-exclusivity event in its history. But the industry risks misreading the event by applying the mental model of the last patent cliff to a fundamentally different market structure. The 2010-2014 cliff was a generic-substitution event. The 2026- 2034 cliff will be a specialty-channel control event.